Is MEDP a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Medpace Holdings (MEDP) rests on Biotech-focused organic model: Medpace concentrates on small and mid-cap biotech sponsors and complex trials rather than scaling through acquisitions like larger peers. Q1 2026 revenue is ~$707M (up ~26.5% YoY). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The biggest near-term concern is booking softness: net book-to-bill fell to roughly 0.88 in Q1 2026 as cancellations hit a multi-quarter high, which can slow future revenue if it persists. Whether MEDP is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Medpace Holdings is a full-service, global clinical contract research organization that designs and runs Phase I through Phase IV clinical trials for biotechnology, pharmaceutical, and medical device companies. The business is deliberately concentrated on small and mid-sized biotech sponsors and complex therapeutic areas, and it employs roughly 6,300 people across more than 40 countries. Unlike larger peers that grow heavily through acquisition, Medpace has scaled organically, which has helped it post unusually strong margins and returns on capital for the sector. The investment picture in 2026 is a contrast between excellent operating quality and softening leading indicators. Revenue is still growing at a double-digit pace and profitability remains high, but net book-to-bill has dipped below 1.0 as trial cancellations rose to the highest level in more than a year, raising questions about the pace of future revenue. Layered on top is a market-wide worry that AI tools could reduce the labor content of running trials and pressure CRO pricing over time, which drove a large valuation reset off the stock's highs.
What's the case for buying MEDP?
1. Biotech-focused organic model
Medpace concentrates on small and mid-cap biotech sponsors and complex trials rather than scaling through acquisitions like larger peers. This focus supports premium pricing and deep therapeutic expertise, and it has produced sector-leading margins and returns on invested capital.
2. Backlog conversion engine
The company carries a backlog of roughly $2.8-2.9 billion, with around $1.9 billion expected to convert into revenue over the next 12 months. That committed work provides near-term revenue visibility even when new bookings slow, cushioning quarterly results.
3. Margin and capital efficiency
Medpace runs high EBITDA margins (low-20s percent) and an exceptionally high return on invested capital, unusual even among quality CROs. Strong operating cash flow and a light capital-spending model let it fund growth internally and repurchase shares.
4. Biotech funding and demand cycle
As biotech funding recovers, demand for outsourced trial execution can reaccelerate, and Medpace's sponsor base positions it to capture that. A healthier funding environment would help lift book-to-bill back above 1.0.
What are the risks to MEDP?
The biggest near-term concern is booking softness: net book-to-bill fell to roughly 0.88 in Q1 2026 as cancellations hit a multi-quarter high, which can slow future revenue if it persists. Medpace's heavy exposure to small and mid-cap biotech makes it sensitive to swings in biotech funding and sentiment. A market-wide fear that AI will reduce the labor and pricing of clinical trials has compressed CRO valuations, and management itself expects AI spending to exceed savings through 2026-2027. Trial cancellations, delays, and sponsor consolidation can create lumpy results, and competition from far larger CROs (IQVIA, ICON, and others) is intense. The stock has been volatile, falling sharply from its 52-week high.
How is MEDP valued? (as of JULY 2026)
Snapshot for MEDP as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Q1 2026 revenue: ~$707M (up ~26.5% YoY)
- Q1 2026 diluted EPS: ~$4.28
- 2026 revenue guidance: ~$2.76-2.86B
- 2026 EPS guidance: ~$16.68-17.50
- EBITDA margin: ~21%
- Forward P/E: ~24x
Medpace beat on earnings but the stock fell sharply after Q1 2026 as net book-to-bill dropped below 1.0 and cancellations rose. Shares had already declined roughly a third from their 52-week high (near $629) toward the low $400s amid AI-disruption fears. The forward multiple has compressed from higher pre-selloff levels while the company still guides to high-single to low-double-digit revenue growth.
How do you decide if MEDP is a buy?
Rather than asking whether MEDP is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MEDP indirectly through an index or sector ETF before adding more.
For the full picture, see the MEDP stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MEDP against your real portfolio and see your actual exposure before deciding.
The bottom line on MEDP
The bottom line: Medpace Holdings's story right now is Biotech-focused organic model, with q1 2026 revenue at ~$707M (up ~26.5% YoY). If you believe that narrative continues, the call is about sizing MEDP sensibly and checking overlap with what you own; if you doubt it (the risk: the biggest near-term concern is booking softness: net book-to-bill fell to roughly 0.88 in Q1 2026 as cancellations hit a multi-quarter high, which can slow future revenue if it persists.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around MEDP with Walnut
Use Medpace Holdings as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is MEDP a good stock to buy right now?
+
The case for Medpace Holdings right now is Biotech-focused organic model, with q1 2026 revenue at ~$707M (up ~26.5% YoY). If you believe that thesis holds, MEDP is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the biggest near-term concern is booking softness: net book-to-bill fell to roughly 0.88 in Q1 2026 as cancellations hit a multi-quarter high, which can slow future revenue if it persists. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Medpace Holdings do?
+
Medpace Holdings is a full-service, global clinical contract research organization that designs and runs Phase I through Phase IV clinical trials for biotechnology, pharmaceutical,
What are the main risks of MEDP?
+
The biggest near-term concern is booking softness: net book-to-bill fell to roughly 0.88 in Q1 2026 as cancellations hit a multi-quarter high, which can slow future revenue if it persists. Medpace's heavy exposure to small and mid-cap biotech makes it sensitive to swings in biotech funding and sentiment. A market-wide fear that AI will reduce the labor and pricing of clinical trials has compressed CRO valuations, and management itself expects AI spending to exceed savings through 2026-2027. Trial cancellations, delays, and sponsor consolidation can create lumpy results, and competition from far larger CROs (IQVIA, ICON, and others) is intense. The stock has been volatile, falling sharply from its 52-week high.
What does Medpace do?
+
Medpace is a clinical contract research organization (CRO) that plans and runs clinical trials (Phase I through Phase IV) for biotech, pharmaceutical, and medical device companies. Sponsors outsource trial design, patient enrollment, monitoring, and regulatory work to Medpace.
Is Medpace profitable?
+
Yes. Medpace is consistently profitable with high margins, reporting roughly $707 million of revenue and about $4.28 diluted EPS in Q1 2026, and it generates strong operating cash flow with an EBITDA margin around 21 percent.
Why did MEDP stock drop in 2026?
+
Despite beating earnings, shares fell sharply after Q1 2026 because net book-to-bill dipped below 1.0 and cancellations reached a multi-quarter high. Broader worries that AI could disrupt CRO economics also pressured the whole sector.
What is book-to-bill and why does it matter for Medpace?
+
Book-to-bill compares net new bookings to revenue in a period. A ratio below 1.0 (about 0.88 in Q1 2026) signals that new business is being booked slower than revenue is recognized, which can foreshadow slower future growth.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell MEDP; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.